Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hyperglycemia

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Hypoglycemia

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Acute Pancreatitis II: Clinical Manifestations and Management

Acute Pancreatitis II: Clinical Manifestations and Management

Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Opportunities and challenges in delivering remote primary care during the Coronavirus outbreak.

BMC primary care·2022

Same author

Correction to: Hypoglycemia, Malnutrition and Body Composition.

Advances in experimental medicine and biology·2020

Same author

Hypoglycemia, Malnutrition and Body Composition.

Advances in experimental medicine and biology·2020

Same author

Reduction of serum albumin in non-critically ill patients during hospitalization is associated with incident hypoglycaemia.

Diabetes & metabolism·2019

Same author

Association of albumin and cholesterol levels with incidence of hypoglycaemia in people admitted to general internal medicine units.

Diabetic medicine : a journal of the British Diabetic Association·2018

Same author

Effect of short- and long-term diabetes control on in-hospital and one year mortality rates in hospitalized patients with diabetic foot.

European journal of internal medicine·2018

Same journal

RETRACTION: Prediction of Arrhythmia Recurrence after Atrial Fibrillation Ablation in Patients with Normal Anatomy of the Left Atrium.

International journal of clinical practice·2025

Same journal

Clinical Outcomes Based on the Attainment of Low-Density Lipoprotein Cholesterol Targets in Patients with Acute Coronary Syndrome in Real-World Practice.

International journal of clinical practice·2025

Same journal

Knowledge and Awareness of Osteoporosis: A Survey of Physical Therapy Providers in Saudi Arabia.

International journal of clinical practice·2024

Same journal

Efficacy and Safety of Pericapsular Nerve Group Block for Hip Fracture Surgery under Spinal Anesthesia: A Meta-Analysis.

International journal of clinical practice·2024

Same journal

The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases.

International journal of clinical practice·2024

Same journal

Blood Features Associated with Viral Infection Severity: An Experience from COVID-19-Pandemic Patients Hospitalized in the Center of Iran, Yazd.

International journal of clinical practice·2024

See all related articles

Search research articles

Related Experiment Video

Updated: May 3, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Inpatient hyperglycaemia improvement quality program.

Y Bar-Dayan¹, Z Landau, M Boaz

¹Diabetes Unit, Wolfson Medical Center, Holon, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

International Journal of Clinical Practice

|January 23, 2014

Summary

This summary is machine-generated.

The Inpatient Hyperglycaemia Improvement Quality Program (IHIQP) significantly improved inpatient glycaemic control over four years. This quality improvement initiative demonstrated sustained positive effects on blood glucose management for hospitalized patients.

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Related Experiment Videos

Last Updated: May 3, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Area of Science:

Clinical Medicine
Endocrinology
Quality Improvement in Healthcare

Background:

Poorly controlled hyperglycemia in hospitalized patients is linked to increased morbidity and mortality.
Hospitalization presents a critical opportunity to enhance patient care and health outcomes.
The Inpatient Hyperglycaemia Improvement Quality Program (IHIQP) was established to address this challenge.

Purpose of the Study:

To assess the effectiveness of the Inpatient Hyperglycaemia Improvement Quality Program (IHIQP).
To evaluate the program's impact on glycaemic control in hospitalized patients over a 4-year period.

Main Methods:

A pre-test post-test design was employed to evaluate the IHIQP.
Key interventions included an institution-wide blood glucose monitoring system, a hospital care protocol aligned with 2007 American Diabetes Association Standards, a multidisciplinary care team, and comprehensive patient education.
Data were collected from August 2007 to October 2011.

Main Results:

Mean blood glucose levels decreased significantly from 196.4 ± 98.4 mg/dl pre-program to 174.5 ± 82.0 mg/dl post-program (p < 0.0001).
The prevalence of severe hyperglycemia (≥ 300 mg/dl) decreased from 13.6% to 8.4% (p < 0.0001).
The proportion of patients achieving in-target blood glucose levels (80-180 mg/dl) increased from 47.7% to 58.1% (p < 0.0001).

Conclusions:

The IHIQP successfully improved inpatient glycaemic control, with effects sustained over time.
Further follow-up is required to determine the program's impact on inpatient mortality and morbidity.